Literature DB >> 2661053

Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications.

J T Willerson1, P Golino, J Eidt, W B Campbell, L M Buja.   

Abstract

We have speculated previously that the abrupt conversion from chronic stable to unstable angina and the continuum to acute myocardial infarction may result from myocardial ischemia caused by progressive platelet aggregation and dynamic vasoconstriction themselves caused by local increases in thromboxane and serotonin at sites of coronary artery stenosis and endothelial injury. Platelet aggregation and dynamic coronary artery vasoconstriction probably result from the local accumulation of thromboxane and serotonin and also relative decreases in the local concentrations of endothelially derived vasodilators and inhibitors of platelet aggregation, such as endothelium-derived relaxing factor (EDRF) and prostacyclin. With severe reductions in coronary blood flow caused by these mechanisms, platelet aggregates may increase, and an occlusive thrombus composed of platelets and white and red blood cells in a fibrin mesh may develop. When coronary arteries are occluded or narrowed for a sufficient period of time by these mechanisms, myocardial necrosis, electrical instability, or sudden death may occur. We believe that unstable angina and acute myocardial infarction are a continuum in relation to the process of coronary artery thrombosis and vasoconstriction. When the period of platelet aggregation or dynamic vasoconstriction at sites of endothelial injury and coronary artery stenosis is brief, unstable angina or non-Q wave infarction may occur. However, when the coronary artery obstruction by these mechanisms is prolonged for several hours, Q wave myocardial infarction results. Chronic endothelial injury and coronary artery stenosis are probably associated with the accumulation of platelets, white and red blood cells, and a fibrin mesh at the site of stenosis and endothelial injury.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2661053     DOI: 10.1161/01.cir.80.1.198

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  46 in total

Review 1.  Function and clinical significance of platelet-derived microparticles.

Authors:  S Nomura
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

Review 2.  Critical review of unstable angina and non-ST elevation myocardial infarction.

Authors:  P J Sheridan; D C Crossman
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

3.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

Review 4.  Glycoprotein IIb/IIIa receptor antagonists in the treatment of acute ST elevation MI: from hypotheses to unexpected recent observations.

Authors:  Allan M Ross
Journal:  J Thromb Thrombolysis       Date:  2003-04       Impact factor: 2.300

Review 5.  Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 1).

Authors:  Shehzad Sami; James T Willerson
Journal:  Tex Heart Inst J       Date:  2010

6.  Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

7.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 8.  Pleiotropic effects of statins.

Authors:  James K Liao; Ulrich Laufs
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

9.  5-HT1-like and 5-HT2A receptors mediate 5-hydroxytryptamine-induced contraction of rabbit isolated mesenteric artery.

Authors:  O Yildiz; M Tuncer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

Review 10.  Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty.

Authors:  J M Wilson; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.